# US 2015/0105264 A1 · Method and system for identifying types of twins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105264 A1
- Document ID: US20150105264A1
- Status: Published application
- Kind: A1
- Application number: 14/395,074
- Filed: 2012-05-23
- Published: 2015-04-16
- Earliest claimed: 2012-05-23
- Assignees: Bgi Diagnosis Co., Ltd.
- Inventors: Huijuan Ge; Jing Zheng; Shang Yi; Xuchao Li; Jian Wang; Jun Wang; Huanming Yang; Xiuqing Zhang
- Web page: https://patentgrep.com/patent/US20150105264A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6888: for detection or identification of organisms
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are a method and a system for identifying whether the twins are dizygotic twins, the method comprising: typing at least one polymorphic loci of the twins fetuses to obtain the fetal polymorphism types, comparing the fetal polymorphism types with the corresponding polymorphism types of their parents, determining whether the twins are dizygotic twins on the basis of the comparison result.

## Claims

### Claim 1

A method of determining whether twins are fraternal twins, comprising following steps:
genotyping at least one polymorphic site of fetuses of the twins, to obtain polymorphism type of the fetuses;
comparing the polymorphism type of the fetuses with corresponding polymorphic site of parents thereof; and
determining whether the twins are the fraternal twins based on a comparing result.

### Claim 2 (depends on 1)

The method of claim 1, wherein the step of genotyping at least one polymorphic site of the fetuses of the twins further comprises:
extracting a nucleic acid sample of the fetuses from a pregnant sample;
constructing a sequencing library for the nucleic acid sample of the fetuses;
subjecting the sequencing library to sequencing, to obtain a sequencing result; and
determining the polymorphism type of the fetuses based on the sequencing result.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pregnant sample is selected from a group consisting of peripheral blood, pregnant woman urine and breast milk.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pregnant sample is peripheral blood.

### Claim 5 (depends on 2)

The method of claim 2, prior to the step of constructing the sequencing library, further comprising:
subjecting the nucleic acid sample of the fetuses to amplifying, to obtain an amplification product containing the polymorphic site, for constructing the sequencing library.

### Claim 6 (depends on 5)

The method of claim 5, wherein the amplification product has a length of 150 bp or less.

### Claim 7 (depends on 2)

The method of claim 2, wherein the polymorphism is selected from a group consisting of STR, VNTR, RFLP, STS, SSCP, CAPS and SNP.

### Claim 8 (depends on 7)

The method of claim 7, wherein the polymorphic site is an STR polymorphic site being at least one selected from a group consisting of vWA, TPDX, D3S1358, D16S539, D5S818, CSF1PO, D11S2368, D2S1338, D8S1179, D13S317, D21S1437, D16S3391, Penta E, D12S1064, D12S391, D6S1043 and D19S433.

### Claim 9 (depends on 8)

The method of claim 8, wherein the nucleic acid sample of the fetuses is subjected to amplifying by PCR, and
for vWA, oligonucleotides shown as SEQ ID NO: 1 and SEQ ID NO: 2 are used as PCR primers;
for TPDX, oligonucleotides shown as SEQ ID NO: 3 and SEQ ID NO: 4 are used as PCR primers;
for D3S1358, oligonucleotides shown as SEQ ID NO: 5 and SEQ ID NO: 6 are used as PCR primers;
for D16S539, oligonucleotides shown as SEQ ID NO: 7 and SEQ ID NO: 8 are used as PCR primers;
for D5S818, oligonucleotides shown as SEQ ID NO: 9 and SEQ ID NO: 10 are used as PCR primers;
for CSF1PO, oligonucleotides shown as SEQ ID NO: 11 and SEQ ID NO: 12 are used as PCR primers;
for D11S2368, oligonucleotides shown as SEQ ID NO: 13 and SEQ ID NO: 14 are used as PCR primers;
for D2S1338, oligonucleotides shown as SEQ ID NO: 15 and SEQ ID NO: 16 are used as PCR primers;
for D8S1179, oligonucleotides shown as SEQ ID NO: 17 and SEQ ID NO: 18 are used as PCR primers;
for D13S317, oligonucleotides shown as SEQ ID NO: 19 and SEQ ID NO: 20 are used as PCR primers;
for D21S1437, oligonucleotides shown as SEQ ID NO: 21 and SEQ ID NO: 22 are used as PCR primers;
for D16S3391, oligonucleotides shown as SEQ ID NO: 23 and SEQ ID NO: 24 are used as PCR primers;
for Penta E, oligonucleotides shown as SEQ ID NO: 25 and SEQ ID NO: 26 are used as PCR primers;
for D12S1064, oligonucleotides shown as SEQ ID NO: 27 and SEQ ID NO: 28 are used as PCR primers;
for D12S391, oligonucleotides shown as SEQ ID NO: 29 and SEQ ID NO: 30 are used as PCR primers;
for D6S1043, oligonucleotides shown as SEQ ID NO: 31 and SEQ ID NO: 32 are used as PCR primers;
for D19S433, oligonucleotides shown as SEQ ID NO: 33 and SEQ ID NO: 34 are used as PCR primers.

### Claim 10

A system for determining whether twins are fraternal twins, comprising:
a genotyping apparatus, for subjecting at least one polymorphic site of fetuses of the twins to genotyping, to obtain polymorphism type of the fetuses;
an analyzing apparatus, connected with the genotyping apparatus, and suitable for comparing the polymorphism type of the fetuses with corresponding polymorphic site of parents thereof; and determining whether the twins are the fraternal twins based on a comparing result.

### Claim 11 (depends on 10)

The system of claim 10, wherein the genotyping apparatus further comprises:
a nucleic acid extracting unit, for extracting a nucleic acid sample of the fetuses from a pregnant sample;
a library constructing unit, connected to the nucleic acid extracting unit, and suitable for constructing a sequencing library for the nucleic acid sample of the fetuses;
a sequencing unit, connected to the library constructing unit, and suitable for subjecting the sequencing library sequencing, to obtain a sequencing result; and
a genotype determining unit, connected to the sequencing unit, and suitable for determining the polymorphism type of the fetuses.

### Claim 12 (depends on 10)

The system of claim 10, wherein the genotyping apparatus further comprises:
an amplifying unit, connected to the nucleic acid extracting unit and library constructing unit respectively, and suitable for subjecting the nucleic acid sample of the fetuses to amplifying, to obtain an amplification product containing the polymorphic site, for constructing the sequencing library.

### Claim 13 (depends on 12)

The system of claim 12, wherein the polymorphism is selected from a group consisting of STR, VNTR, RFLP, STS, SSCP, CAPS and SNP.

### Claim 14 (depends on 13)

The system of claim 13, wherein the polymorphic site is an STR polymorphic site being at least one selected from a group consisting of vWA, TPDX, D3S1358, D16S539, D5S818, CSF1PO, D11S2368, D2S1338, D8S1179, D13S317, D21S1437, D16S3391, Penta E, D12S1064, D12S391, D6S1043 and D19S433.

### Claim 15 (depends on 14)

The system of claim 14, wherein the amplifying unit is equipped with the primers, for subjecting the nucleic acid sample of the fetuses to amplifying by PCR, and for vWA, oligonucleotides shown as SEQ ID NO: 1 and SEQ ID NO: 2 are used as PCR primers;
for TPDX, oligonucleotides shown as SEQ ID NO: 3 and SEQ ID NO: 4 are used as PCR primers;
for D3S1358, oligonucleotides shown as SEQ ID NO: 5 and SEQ ID NO: 6 are used as PCR primers;
for D16S539, oligonucleotides shown as SEQ ID NO: 7 and SEQ ID NO: 8 are used as PCR primers;
for D5S818, oligonucleotides shown as SEQ ID NO: 9 and SEQ ID NO: 10 are used as PCR primers;
for CSF1PO, oligonucleotides shown as SEQ ID NO: 11 and SEQ ID NO: 12 are used as PCR primers;
for D11S2368, oligonucleotides shown as SEQ ID NO: 13 and SEQ ID NO: 14 are used as PCR primers;
for D2S1338, oligonucleotides shown as SEQ ID NO: 15 and SEQ ID NO: 16 are used as PCR primers;
for D8S1179, oligonucleotides shown as SEQ ID NO: 17 and SEQ ID NO: 18 are used as PCR primers;
for D13S317, oligonucleotides shown as SEQ ID NO: 19 and SEQ ID NO: 20 are used as PCR primers;
for D21S1437, oligonucleotides shown as SEQ ID NO: 21 and SEQ ID NO: 22 are used as PCR primers;
for D16S3391, oligonucleotides shown as SEQ ID NO: 23 and SEQ ID NO: 24 are used as PCR primers;
for Penta E, oligonucleotides shown as SEQ ID NO: 25 and SEQ ID NO: 26 are used as PCR primers;
for D12S1064, oligonucleotides shown as SEQ ID NO: 27 and SEQ ID NO: 28 are used as PCR primers;
for D12S391, oligonucleotides shown as SEQ ID NO: 29 and SEQ ID NO: 30 are used as PCR primers;
for D6S1043, oligonucleotides shown as SEQ ID NO: 31 and SEQ ID NO: 32 are used as PCR primers;
for D19S433, oligonucleotides shown as SEQ ID NO: 33 and SEQ ID NO: 34 are used as PCR primers.
